Report Detail

Pharma & Healthcare Global and Japan Influenza (Flu) Antiviral Drugs Market Size, Status and Forecast 2021-2027

  • RnM4345402
  • |
  • 27 September, 2021
  • |
  • Global
  • |
  • 116 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Market Analysis by Type
    • 1.2.1 Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
  • 1.2.2 Penetration and Dehulling Inhibitors
  • 1.2.3 DNA Polymerase Inhibitors
  • 1.2.4 Reverse Transcriptase Inhibitors
  • 1.2.5 Protein Inhibitors
  • 1.2.6 Neuraminidase Inhibitors
  • 1.2.7 Broad-spectrum Antiviral Drugs
  • 1.3 Market by Application
  • 1.3.1 Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2016 VS 2021 VS 2027
  • 1.3.2 Hospital
  • 1.3.3 Clinic
  • 1.3.4 Household
  • 1.3.5 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered
  • 2 Global Growth Trends

    • 2.1 Global Influenza (Flu) Antiviral Drugs Market Perspective (2016-2027)
    • 2.2 Influenza (Flu) Antiviral Drugs Growth Trends by Regions
    • 2.2.1 Influenza (Flu) Antiviral Drugs Market Size by Regions: 2016 VS 2021 VS 2027
  • 2.2.2 Influenza (Flu) Antiviral Drugs Historic Market Share by Regions (2016-2021)
  • 2.2.3 Influenza (Flu) Antiviral Drugs Forecasted Market Size by Regions (2022-2027)
  • 2.3 Influenza (Flu) Antiviral Drugs Industry Dynamic
  • 2.3.1 Influenza (Flu) Antiviral Drugs Market Trends
  • 2.3.2 Influenza (Flu) Antiviral Drugs Market Drivers
  • 2.3.3 Influenza (Flu) Antiviral Drugs Market Challenges
  • 2.3.4 Influenza (Flu) Antiviral Drugs Market Restraints
  • 3 Competition Landscape by Key Players

    • 3.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue
    • 3.1.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue (2016-2021)
  • 3.1.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Players (2016-2021)
  • 3.2 Global Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Influenza (Flu) Antiviral Drugs Revenue
  • 3.4 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio
  • 3.4.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
  • 3.4.2 Global Top 10 and Top 5 Companies by Influenza (Flu) Antiviral Drugs Revenue in 2020
  • 3.5 Influenza (Flu) Antiviral Drugs Key Players Head office and Area Served
  • 3.6 Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
  • 3.7 Date of Enter into Influenza (Flu) Antiviral Drugs Market
  • 3.8 Mergers & Acquisitions, Expansion Plans
  • 4 Influenza (Flu) Antiviral Drugs Breakdown Data by Type

    • 4.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Type (2016-2021)
    • 4.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2022-2027)

    5 Influenza (Flu) Antiviral Drugs Breakdown Data by Application

    • 5.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Application (2016-2021)
    • 5.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2022-2027)

    6 North America

    • 6.1 North America Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
    • 6.2 North America Influenza (Flu) Antiviral Drugs Market Size by Type
    • 6.2.1 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
  • 6.2.2 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
  • 6.2.3 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
  • 6.3 North America Influenza (Flu) Antiviral Drugs Market Size by Application
  • 6.3.1 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
  • 6.3.2 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
  • 6.3.3 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
  • 6.4 North America Influenza (Flu) Antiviral Drugs Market Size by Country
  • 6.4.1 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
  • 6.4.2 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
  • 6.4.3 United States
  • 6.4.4 Canada
  • 7 Europe

    • 7.1 Europe Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
    • 7.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Type
    • 7.2.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
  • 7.2.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
  • 7.2.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
  • 7.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Application
  • 7.3.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
  • 7.3.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
  • 7.3.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
  • 7.4 Europe Influenza (Flu) Antiviral Drugs Market Size by Country
  • 7.4.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
  • 7.4.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
  • 7.4.3 Germany
  • 7.4.4 France
  • 7.4.5 U.K.
  • 7.4.6 Italy
  • 7.4.7 Russia
  • 7.4.8 Nordic
  • 8 Asia-Pacific

    • 8.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
    • 8.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type
    • 8.2.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
  • 8.2.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
  • 8.2.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application
  • 8.3.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
  • 8.3.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
  • 8.3.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region
  • 8.4.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2016-2021)
  • 8.4.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2022-2027)
  • 8.4.3 China
  • 8.4.4 Japan
  • 8.4.5 South Korea
  • 8.4.6 Southeast Asia
  • 8.4.7 India
  • 8.4.8 Australia
  • 9 Latin America

    • 9.1 Latin America Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
    • 9.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type
    • 9.2.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
  • 9.2.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
  • 9.2.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
  • 9.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application
  • 9.3.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
  • 9.3.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
  • 9.3.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
  • 9.4 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country
  • 9.4.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
  • 9.4.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
  • 9.4.3 Mexico
  • 9.4.4 Brazil
  • 10 Middle East & Africa

    • 10.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
    • 10.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type
    • 10.2.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
  • 10.2.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
  • 10.2.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application
  • 10.3.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
  • 10.3.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
  • 10.3.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country
  • 10.4.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
  • 10.4.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
  • 10.4.3 Turkey
  • 10.4.4 Saudi Arabia
  • 10.4.5 UAE
  • 11 Key Players Profiles

    • 11.1 Pfizer
    • 11.1.1 Pfizer Company Details
  • 11.1.2 Pfizer Business Overview
  • 11.1.3 Pfizer Influenza (Flu) Antiviral Drugs Introduction
  • 11.1.4 Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.1.5 Pfizer Recent Development
  • 11.2 Roche
  • 11.2.1 Roche Company Details
  • 11.2.2 Roche Business Overview
  • 11.2.3 Roche Influenza (Flu) Antiviral Drugs Introduction
  • 11.2.4 Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.2.5 Roche Recent Development
  • 11.3 Sanofi
  • 11.3.1 Sanofi Company Details
  • 11.3.2 Sanofi Business Overview
  • 11.3.3 Sanofi Influenza (Flu) Antiviral Drugs Introduction
  • 11.3.4 Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.3.5 Sanofi Recent Development
  • 11.4 Johnson & Johnson
  • 11.4.1 Johnson & Johnson Company Details
  • 11.4.2 Johnson & Johnson Business Overview
  • 11.4.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Introduction
  • 11.4.4 Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.4.5 Johnson & Johnson Recent Development
  • 11.5 Merck & Co. (MSD)
  • 11.5.1 Merck & Co. (MSD) Company Details
  • 11.5.2 Merck & Co. (MSD) Business Overview
  • 11.5.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Introduction
  • 11.5.4 Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.5.5 Merck & Co. (MSD) Recent Development
  • 11.6 Novartis
  • 11.6.1 Novartis Company Details
  • 11.6.2 Novartis Business Overview
  • 11.6.3 Novartis Influenza (Flu) Antiviral Drugs Introduction
  • 11.6.4 Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.6.5 Novartis Recent Development
  • 11.7 AbbVie
  • 11.7.1 AbbVie Company Details
  • 11.7.2 AbbVie Business Overview
  • 11.7.3 AbbVie Influenza (Flu) Antiviral Drugs Introduction
  • 11.7.4 AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.7.5 AbbVie Recent Development
  • 11.8 Gilead Sciences
  • 11.8.1 Gilead Sciences Company Details
  • 11.8.2 Gilead Sciences Business Overview
  • 11.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Introduction
  • 11.8.4 Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.8.5 Gilead Sciences Recent Development
  • 11.9 GlaxoSmithKline (GSK)
  • 11.9.1 GlaxoSmithKline (GSK) Company Details
  • 11.9.2 GlaxoSmithKline (GSK) Business Overview
  • 11.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Introduction
  • 11.9.4 GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.9.5 GlaxoSmithKline (GSK) Recent Development
  • 11.10 Amgen
  • 11.10.1 Amgen Company Details
  • 11.10.2 Amgen Business Overview
  • 11.10.3 Amgen Influenza (Flu) Antiviral Drugs Introduction
  • 11.10.4 Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.10.5 Amgen Recent Development
  • 11.11 AstraZeneca
  • 11.11.1 AstraZeneca Company Details
  • 11.11.2 AstraZeneca Business Overview
  • 11.11.3 AstraZeneca Influenza (Flu) Antiviral Drugs Introduction
  • 11.11.4 AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.11.5 AstraZeneca Recent Development
  • 11.12 Bristol-Myers Squibb
  • 11.12.1 Bristol-Myers Squibb Company Details
  • 11.12.2 Bristol-Myers Squibb Business Overview
  • 11.12.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Introduction
  • 11.12.4 Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.12.5 Bristol-Myers Squibb Recent Development
  • 11.13 Eli Lilly
  • 11.13.1 Eli Lilly Company Details
  • 11.13.2 Eli Lilly Business Overview
  • 11.13.3 Eli Lilly Influenza (Flu) Antiviral Drugs Introduction
  • 11.13.4 Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.13.5 Eli Lilly Recent Development
  • 11.14 Teva
  • 11.14.1 Teva Company Details
  • 11.14.2 Teva Business Overview
  • 11.14.3 Teva Influenza (Flu) Antiviral Drugs Introduction
  • 11.14.4 Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.14.5 Teva Recent Development
  • 11.15 Bayer
  • 11.15.1 Bayer Company Details
  • 11.15.2 Bayer Business Overview
  • 11.15.3 Bayer Influenza (Flu) Antiviral Drugs Introduction
  • 11.15.4 Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.15.5 Bayer Recent Development
  • 11.16 Novo Nordisk
  • 11.16.1 Novo Nordisk Company Details
  • 11.16.2 Novo Nordisk Business Overview
  • 11.16.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Introduction
  • 11.16.4 Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.16.5 Novo Nordisk Recent Development
  • 11.17 Allergan
  • 11.17.1 Allergan Company Details
  • 11.17.2 Allergan Business Overview
  • 11.17.3 Allergan Influenza (Flu) Antiviral Drugs Introduction
  • 11.17.4 Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.17.5 Allergan Recent Development
  • 11.18 Takeda
  • 11.18.1 Takeda Company Details
  • 11.18.2 Takeda Business Overview
  • 11.18.3 Takeda Influenza (Flu) Antiviral Drugs Introduction
  • 11.18.4 Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
  • 11.18.5 Takeda Recent Development
  • 11.18 Boehringer Ingelheim
  • .1 Boehringer Ingelheim Company Details

      .2 Boehringer Ingelheim Business Overview

        .3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Introduction

          .4 Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)

            .5 Boehringer Ingelheim Recent Development

              12 Analyst's Viewpoints/Conclusions

                13 Appendix

                • 13.1 Research Methodology
                • 13.1.1 Methodology/Research Approach
              • 13.1.2 Data Source
              • 13.2 Disclaimer
              • 13.3 Author Details1 Report Overview
              • 1.1 Study Scope
              • 1.2 Market Analysis by Type
                • 1.2.1 Global Influenza (Flu) Antiviral Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
                • 1.2.2 Penetration and Dehulling Inhibitors
                • 1.2.3 DNA Polymerase Inhibitors
                • 1.2.4 Reverse Transcriptase Inhibitors
                • 1.2.5 Protein Inhibitors
                • 1.2.6 Neuraminidase Inhibitors
                • 1.2.7 Broad-spectrum Antiviral Drugs
              • 1.3 Market by Application
                • 1.3.1 Global Influenza (Flu) Antiviral Drugs Market Share by Application: 2016 VS 2021 VS 2027
                • 1.3.2 Hospital
                • 1.3.3 Clinic
                • 1.3.4 Household
                • 1.3.5 Others
              • 1.4 Study Objectives
              • 1.5 Years Considered
              • 2 Global Growth Trends

                • 2.1 Global Influenza (Flu) Antiviral Drugs Market Perspective (2016-2027)
                • 2.2 Influenza (Flu) Antiviral Drugs Growth Trends by Regions
                  • 2.2.1 Influenza (Flu) Antiviral Drugs Market Size by Regions: 2016 VS 2021 VS 2027
                  • 2.2.2 Influenza (Flu) Antiviral Drugs Historic Market Share by Regions (2016-2021)
                  • 2.2.3 Influenza (Flu) Antiviral Drugs Forecasted Market Size by Regions (2022-2027)
                • 2.3 Influenza (Flu) Antiviral Drugs Industry Dynamic
                  • 2.3.1 Influenza (Flu) Antiviral Drugs Market Trends
                  • 2.3.2 Influenza (Flu) Antiviral Drugs Market Drivers
                  • 2.3.3 Influenza (Flu) Antiviral Drugs Market Challenges
                  • 2.3.4 Influenza (Flu) Antiviral Drugs Market Restraints

                3 Competition Landscape by Key Players

                • 3.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue
                  • 3.1.1 Global Top Influenza (Flu) Antiviral Drugs Players by Revenue (2016-2021)
                  • 3.1.2 Global Influenza (Flu) Antiviral Drugs Revenue Market Share by Players (2016-2021)
                • 3.2 Global Influenza (Flu) Antiviral Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
                • 3.3 Players Covered: Ranking by Influenza (Flu) Antiviral Drugs Revenue
                • 3.4 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio
                  • 3.4.1 Global Influenza (Flu) Antiviral Drugs Market Concentration Ratio (CR5 and HHI)
                  • 3.4.2 Global Top 10 and Top 5 Companies by Influenza (Flu) Antiviral Drugs Revenue in 2020
                • 3.5 Influenza (Flu) Antiviral Drugs Key Players Head office and Area Served
                • 3.6 Key Players Influenza (Flu) Antiviral Drugs Product Solution and Service
                • 3.7 Date of Enter into Influenza (Flu) Antiviral Drugs Market
                • 3.8 Mergers & Acquisitions, Expansion Plans

                4 Influenza (Flu) Antiviral Drugs Breakdown Data by Type

                • 4.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Type (2016-2021)
                • 4.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Type (2022-2027)

                5 Influenza (Flu) Antiviral Drugs Breakdown Data by Application

                • 5.1 Global Influenza (Flu) Antiviral Drugs Historic Market Size by Application (2016-2021)
                • 5.2 Global Influenza (Flu) Antiviral Drugs Forecasted Market Size by Application (2022-2027)

                6 North America

                • 6.1 North America Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
                • 6.2 North America Influenza (Flu) Antiviral Drugs Market Size by Type
                  • 6.2.1 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
                  • 6.2.2 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
                  • 6.2.3 North America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
                • 6.3 North America Influenza (Flu) Antiviral Drugs Market Size by Application
                  • 6.3.1 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
                  • 6.3.2 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
                  • 6.3.3 North America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
                • 6.4 North America Influenza (Flu) Antiviral Drugs Market Size by Country
                  • 6.4.1 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
                  • 6.4.2 North America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
                  • 6.4.3 United States
                  • 6.4.4 Canada

                7 Europe

                • 7.1 Europe Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
                • 7.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Type
                  • 7.2.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
                  • 7.2.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
                  • 7.2.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
                • 7.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Application
                  • 7.3.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
                  • 7.3.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
                  • 7.3.3 Europe Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
                • 7.4 Europe Influenza (Flu) Antiviral Drugs Market Size by Country
                  • 7.4.1 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
                  • 7.4.2 Europe Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
                  • 7.4.3 Germany
                  • 7.4.4 France
                  • 7.4.5 U.K.
                  • 7.4.6 Italy
                  • 7.4.7 Russia
                  • 7.4.8 Nordic

                8 Asia-Pacific

                • 8.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
                • 8.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type
                  • 8.2.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
                  • 8.2.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
                  • 8.2.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
                • 8.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application
                  • 8.3.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
                  • 8.3.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
                  • 8.3.3 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
                • 8.4 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region
                  • 8.4.1 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2016-2021)
                  • 8.4.2 Asia-Pacific Influenza (Flu) Antiviral Drugs Market Size by Region (2022-2027)
                  • 8.4.3 China
                  • 8.4.4 Japan
                  • 8.4.5 South Korea
                  • 8.4.6 Southeast Asia
                  • 8.4.7 India
                  • 8.4.8 Australia

                9 Latin America

                • 9.1 Latin America Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
                • 9.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type
                  • 9.2.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
                  • 9.2.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
                  • 9.2.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
                • 9.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application
                  • 9.3.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
                  • 9.3.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
                  • 9.3.3 Latin America Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
                • 9.4 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country
                  • 9.4.1 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
                  • 9.4.2 Latin America Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
                  • 9.4.3 Mexico
                  • 9.4.4 Brazil

                10 Middle East & Africa

                • 10.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size (2016-2027)
                • 10.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type
                  • 10.2.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2021)
                  • 10.2.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2022-2027)
                  • 10.2.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Type (2016-2027)
                • 10.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application
                  • 10.3.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2021)
                  • 10.3.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2022-2027)
                  • 10.3.3 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Application (2016-2027)
                • 10.4 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country
                  • 10.4.1 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2016-2021)
                  • 10.4.2 Middle East & Africa Influenza (Flu) Antiviral Drugs Market Size by Country (2022-2027)
                  • 10.4.3 Turkey
                  • 10.4.4 Saudi Arabia
                  • 10.4.5 UAE

                11 Key Players Profiles

                • 11.1 Pfizer
                  • 11.1.1 Pfizer Company Details
                  • 11.1.2 Pfizer Business Overview
                  • 11.1.3 Pfizer Influenza (Flu) Antiviral Drugs Introduction
                  • 11.1.4 Pfizer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.1.5 Pfizer Recent Development
                • 11.2 Roche
                  • 11.2.1 Roche Company Details
                  • 11.2.2 Roche Business Overview
                  • 11.2.3 Roche Influenza (Flu) Antiviral Drugs Introduction
                  • 11.2.4 Roche Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.2.5 Roche Recent Development
                • 11.3 Sanofi
                  • 11.3.1 Sanofi Company Details
                  • 11.3.2 Sanofi Business Overview
                  • 11.3.3 Sanofi Influenza (Flu) Antiviral Drugs Introduction
                  • 11.3.4 Sanofi Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.3.5 Sanofi Recent Development
                • 11.4 Johnson & Johnson
                  • 11.4.1 Johnson & Johnson Company Details
                  • 11.4.2 Johnson & Johnson Business Overview
                  • 11.4.3 Johnson & Johnson Influenza (Flu) Antiviral Drugs Introduction
                  • 11.4.4 Johnson & Johnson Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.4.5 Johnson & Johnson Recent Development
                • 11.5 Merck & Co. (MSD)
                  • 11.5.1 Merck & Co. (MSD) Company Details
                  • 11.5.2 Merck & Co. (MSD) Business Overview
                  • 11.5.3 Merck & Co. (MSD) Influenza (Flu) Antiviral Drugs Introduction
                  • 11.5.4 Merck & Co. (MSD) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.5.5 Merck & Co. (MSD) Recent Development
                • 11.6 Novartis
                  • 11.6.1 Novartis Company Details
                  • 11.6.2 Novartis Business Overview
                  • 11.6.3 Novartis Influenza (Flu) Antiviral Drugs Introduction
                  • 11.6.4 Novartis Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.6.5 Novartis Recent Development
                • 11.7 AbbVie
                  • 11.7.1 AbbVie Company Details
                  • 11.7.2 AbbVie Business Overview
                  • 11.7.3 AbbVie Influenza (Flu) Antiviral Drugs Introduction
                  • 11.7.4 AbbVie Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.7.5 AbbVie Recent Development
                • 11.8 Gilead Sciences
                  • 11.8.1 Gilead Sciences Company Details
                  • 11.8.2 Gilead Sciences Business Overview
                  • 11.8.3 Gilead Sciences Influenza (Flu) Antiviral Drugs Introduction
                  • 11.8.4 Gilead Sciences Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.8.5 Gilead Sciences Recent Development
                • 11.9 GlaxoSmithKline (GSK)
                  • 11.9.1 GlaxoSmithKline (GSK) Company Details
                  • 11.9.2 GlaxoSmithKline (GSK) Business Overview
                  • 11.9.3 GlaxoSmithKline (GSK) Influenza (Flu) Antiviral Drugs Introduction
                  • 11.9.4 GlaxoSmithKline (GSK) Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.9.5 GlaxoSmithKline (GSK) Recent Development
                • 11.10 Amgen
                  • 11.10.1 Amgen Company Details
                  • 11.10.2 Amgen Business Overview
                  • 11.10.3 Amgen Influenza (Flu) Antiviral Drugs Introduction
                  • 11.10.4 Amgen Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.10.5 Amgen Recent Development
                • 11.11 AstraZeneca
                  • 11.11.1 AstraZeneca Company Details
                  • 11.11.2 AstraZeneca Business Overview
                  • 11.11.3 AstraZeneca Influenza (Flu) Antiviral Drugs Introduction
                  • 11.11.4 AstraZeneca Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.11.5 AstraZeneca Recent Development
                • 11.12 Bristol-Myers Squibb
                  • 11.12.1 Bristol-Myers Squibb Company Details
                  • 11.12.2 Bristol-Myers Squibb Business Overview
                  • 11.12.3 Bristol-Myers Squibb Influenza (Flu) Antiviral Drugs Introduction
                  • 11.12.4 Bristol-Myers Squibb Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.12.5 Bristol-Myers Squibb Recent Development
                • 11.13 Eli Lilly
                  • 11.13.1 Eli Lilly Company Details
                  • 11.13.2 Eli Lilly Business Overview
                  • 11.13.3 Eli Lilly Influenza (Flu) Antiviral Drugs Introduction
                  • 11.13.4 Eli Lilly Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.13.5 Eli Lilly Recent Development
                • 11.14 Teva
                  • 11.14.1 Teva Company Details
                  • 11.14.2 Teva Business Overview
                  • 11.14.3 Teva Influenza (Flu) Antiviral Drugs Introduction
                  • 11.14.4 Teva Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.14.5 Teva Recent Development
                • 11.15 Bayer
                  • 11.15.1 Bayer Company Details
                  • 11.15.2 Bayer Business Overview
                  • 11.15.3 Bayer Influenza (Flu) Antiviral Drugs Introduction
                  • 11.15.4 Bayer Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.15.5 Bayer Recent Development
                • 11.16 Novo Nordisk
                  • 11.16.1 Novo Nordisk Company Details
                  • 11.16.2 Novo Nordisk Business Overview
                  • 11.16.3 Novo Nordisk Influenza (Flu) Antiviral Drugs Introduction
                  • 11.16.4 Novo Nordisk Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.16.5 Novo Nordisk Recent Development
                • 11.17 Allergan
                  • 11.17.1 Allergan Company Details
                  • 11.17.2 Allergan Business Overview
                  • 11.17.3 Allergan Influenza (Flu) Antiviral Drugs Introduction
                  • 11.17.4 Allergan Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.17.5 Allergan Recent Development
                • 11.18 Takeda
                  • 11.18.1 Takeda Company Details
                  • 11.18.2 Takeda Business Overview
                  • 11.18.3 Takeda Influenza (Flu) Antiviral Drugs Introduction
                  • 11.18.4 Takeda Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)
                  • 11.18.5 Takeda Recent Development
                • 11.18 Boehringer Ingelheim

                .1 Boehringer Ingelheim Company Details

                  .2 Boehringer Ingelheim Business Overview

                    .3 Boehringer Ingelheim Influenza (Flu) Antiviral Drugs Introduction

                      .4 Boehringer Ingelheim Revenue in Influenza (Flu) Antiviral Drugs Business (2016-2021)

                        .5 Boehringer Ingelheim Recent Development

                          12 Analyst's Viewpoints/Conclusions

                            13 Appendix

                            • 13.1 Research Methodology
                              • 13.1.1 Methodology/Research Approach
                              • 13.1.2 Data Source
                            • 13.2 Disclaimer

                            Antiviral drugs are a class of drugs for the specific treatment of viral infections.
                            Market Analysis and Insights: Global Influenza (Flu) Antiviral Drugs Market
                            The global Influenza (Flu) Antiviral Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
                            With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Influenza (Flu) Antiviral Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Influenza (Flu) Antiviral Drugs market in terms of revenue.
                            On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Influenza (Flu) Antiviral Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Influenza (Flu) Antiviral Drugs market.
                            Influenza (Flu) Antiviral Drugs Breakdown Data by Type
                            Penetration and Dehulling Inhibitors
                            DNA Polymerase Inhibitors
                            Reverse Transcriptase Inhibitors
                            Protein Inhibitors
                            Neuraminidase Inhibitors
                            Broad-spectrum Antiviral Drugs
                            Influenza (Flu) Antiviral Drugs Breakdown Data by Application
                            Hospital
                            Clinic
                            Household
                            Others
                            Based on regional and country-level analysis, the Influenza (Flu) Antiviral Drugs market has been segmented as follows:
                            North America
                            United States
                            Canada
                            Europe
                            Germany
                            France
                            U.K.
                            Italy
                            Russia
                            Nordic
                            Rest of Europe
                            Asia-Pacific
                            China
                            Japan
                            South Korea
                            Southeast Asia
                            India
                            Australia
                            Rest of Asia-Pacific
                            Latin America
                            Mexico
                            Brazil
                            Middle East & Africa
                            Turkey
                            Saudi Arabia
                            UAE
                            Rest of Middle East & Africa
                            In the competitive analysis section of the report, leading as well as prominent players of the global Influenza (Flu) Antiviral Drugs market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2016-2021. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2016-2021.
                            The following players are covered in this report:
                            Pfizer
                            Roche
                            Sanofi
                            Johnson & Johnson
                            Merck & Co. (MSD)
                            Novartis
                            AbbVie
                            Gilead Sciences
                            GlaxoSmithKline (GSK)
                            Amgen
                            AstraZeneca
                            Bristol-Myers Squibb
                            Eli Lilly
                            Teva
                            Bayer
                            Novo Nordisk
                            Allergan
                            Takeda
                            Boehringer Ingelheim


                            Summary:
                            Get latest Market Research Reports on Influenza (Flu) Antiviral Drugs. Industry analysis & Market Report on Influenza (Flu) Antiviral Drugs is a syndicated market report, published as Global and Japan Influenza (Flu) Antiviral Drugs Market Size, Status and Forecast 2021-2027. It is complete Research Study and Industry Analysis of Influenza (Flu) Antiviral Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                            Last updated on

                            REPORT YOU MIGHT BE INTERESTED

                            Purchase this Report

                            $3,500.00
                            $7,000.00
                            2,548.00
                            5,096.00
                            3,013.50
                            6,027.00
                            399,525.00
                            799,050.00
                            262,710.00
                            525,420.00
                            Credit card Logo

                            Related Reports


                            Reason to Buy

                            Request for Sample of this report